Dyadic International (DYAI) Stock Price, Quote & News

Company Profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products f...

Industry: Biotechnology

Sector: Healthcare

Phone: 561 743 8333

Fax: 561 743 8343

Website: www.dyadic.com

Address:

1044 North U.S. Highway One, Suite 201, Jupiter, United States

SmallCapGrowth Apr. 13 at 6:27 PM

$DYAI HIGH ALERT – BIOTECH COMMERCIAL - SUPERHEROSTOCKPICKERS https://investorshangout.com/post/view?id=6824076

0 · Reply

SmallCapGrowth Apr. 13 at 4:11 PM

MOMO'S BREAKOUT BOARD : 🚨 $DYAI HIGH ALERT – BIOTECH COM... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177493776 via @Investors_Hub

0 · Reply

SmallCapGrowth Apr. 13 at 2:59 PM

🚨 $DYAI HIGH ALERT – BIOTECH COMMERCIAL PIVOT IS LIVE! 🚀 Dyadic Applied BioSolutions just dropped multiple commercial launches in 2026: https://finance.yahoo.com/sectors/healthcare/articles/dyai-introducing-albufree-dx-093300678.html #biotechnology #stocks #DYAI @TheBullRunShow

0 · Reply

SmallCapGrowth Apr. 13 at 1:49 PM

🚨 $DYAI HIGH ALERT – BIOTECH COMMERCIAL PIVOT IS LIVE! 🚀 Dyadic Applied BioSolutions just dropped multiple commercial launches in 2026: • AlbuFree™ DX recombinant human albumin LIVE with Proliant • RNase-Free DNase I with Fermbox Bio • Non-animal dairy enzyme heading to market 2026 C1 platform is delivering real revenue + partnerships while this microcap ($32M) is still flying under the radar! Who’s loading the boat before it moons? 👀 Drop your entry below! #DYAI #StockAlert #BiotechStocks #DYAIto3 #HighAlert @TheBullRunShow @DAVANZO

0 · Reply

IChiGOdoranZ Apr. 10 at 6:24 PM

$DYAI Dyadic Applied BioSolutions and Integrated Biotherapeutics, LLC Enter Commercial Distribution Agreement https://www.marketscreener.com/news/dyadic-applied-biosolutions-and-integrated-biotherapeutics-llc-enter-commercial-distribution-agreem-ce7e5edadf88f423

0 · Reply

IChiGOdoranZ Apr. 10 at 5:53 PM

$DYAI Indicators Summary #tradingview https://www.tradingview.com/symbols/NASDAQ-DYAI/technicals/

0 · Reply

IChiGOdoranZ Apr. 10 at 1:07 PM

$DYAI News : #DYAI Dyadic International Inc (DYAI) Q4 2025 Earnings Call Highlights: Navigating Transition with ... https://finance.yahoo.com/sectors/healthcare/articles/dyadic-international-inc-dyai-q4-030048311.html

0 · Reply

Glopolon Apr. 9 at 10:06 PM

$DYAI Poster from WVC https://d2ghdaxqb194v2.cloudfront.net/2606/199728.pdf

0 · Reply

Glopolon Apr. 9 at 10:06 PM

$DYAI https://d2ghdaxqb194v2.cloudfront.net/2606/199727.pdf Presentation material from World Vaccine Congress

0 · Reply

IChiGOdoranZ Apr. 7 at 5:20 PM

$DYAI Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress https://globenewswire.com/news-release/2026/03/25/3262620/0/en/Dyadic-Announces-2025-Financial-Results-and-Highlights-Recent-Company-Progress.html

0 · Reply

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Mar 16, 2026, 7:20 AM EDT - 4 weeks ago

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Mar 11, 2026, 4:10 PM EDT - 4 weeks ago

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

Mar 4, 2026, 7:20 AM EST - 5 weeks ago

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Mar 2, 2026, 7:20 AM EST - 6 weeks ago

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Feb 17, 2026, 7:25 AM EST - 2 months ago

Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

Dec 15, 2025, 7:20 AM EST - 4 months ago

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins

Dec 1, 2025, 7:25 AM EST - 4 months ago

Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets

Nov 12, 2025, 4:05 PM EST - 5 months ago

Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

Oct 29, 2025, 7:25 AM EDT - 5 months ago

Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

Oct 6, 2025, 8:30 AM EDT - 6 months ago

Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments

Sep 4, 2025, 9:00 AM EDT - 7 months ago

Dyadic to Present at Investor Conferences and BPI East

Aug 13, 2025, 4:01 PM EDT - 8 months ago

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Aug 5, 2025, 4:11 PM EDT - 9 months ago

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Jul 31, 2025, 8:47 AM EDT - 9 months ago

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Jul 31, 2025, 7:30 AM EDT - 9 months ago

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Jul 30, 2025, 4:02 PM EDT - 9 months ago

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

Jul 2, 2025, 4:00 PM EDT - 10 months ago

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

Jun 2, 2025, 8:35 AM EDT - 11 months ago

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

May 1, 2025, 3:00 PM EDT - 1 year ago

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Apr 16, 2025, 2:00 PM EDT - 1 year ago

Dyadic to Present at World Vaccine Congress | Washington

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Dyadic Reports 2024 Year-End Financial Results and Business Updates

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

Mar 6, 2025, 8:30 AM EST - 1 year ago

Dyadic to Attend Multiple Industry Events in March

Jan 6, 2025, 8:30 AM EST - 1 year ago

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Nov 21, 2024, 8:30 AM EST - 1 year ago

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Nov 4, 2024, 4:30 PM EST - 1 year ago

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Dyadic Expands Global Presence with Participation in Key Industry Events

Sep 23, 2024, 9:50 AM EDT - 1 year ago

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

Jul 30, 2024, 4:00 PM EDT - 1 year ago

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

May 30, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Attend Industry Events in June

May 14, 2024, 4:00 PM EDT - 2 years ago

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 8, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Industry and Investor Events in May

Apr 30, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Mar 28, 2024, 8:30 AM EDT - 2 years ago

Dyadic Announces Change in Board and Management Leadership Roles

Mar 27, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Industry Events in April

Mar 26, 2024, 8:30 AM EDT - 2 years ago

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Mar 21, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

Mar 14, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

Mar 11, 2024, 9:57 AM EDT - 2 years ago

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 11, 2024, 8:30 AM EDT - 2 years ago

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 1, 2024, 8:30 AM EST - 2 years ago

Dyadic to Attend Industry Events in March

Feb 28, 2024, 8:30 AM EST - 2 years ago

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Feb 23, 2024, 2:00 AM EST - 2 years ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 21, 2024, 8:30 AM EST - 2 years ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 13, 2024, 8:30 AM EST - 2 years ago

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

Feb 6, 2024, 8:30 AM EST - 2 years ago

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

Feb 1, 2024, 8:30 AM EST - 2 years ago

Dyadic to Attend BIO CEO & Investor Conference and European Industry Events

SmallCapGrowth Apr. 13 at 6:27 PM

$DYAI HIGH ALERT – BIOTECH COMMERCIAL - SUPERHEROSTOCKPICKERS https://investorshangout.com/post/view?id=6824076

0 · Reply

SmallCapGrowth Apr. 13 at 4:11 PM

MOMO'S BREAKOUT BOARD : 🚨 $DYAI HIGH ALERT – BIOTECH COM... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177493776 via @Investors_Hub

0 · Reply

SmallCapGrowth Apr. 13 at 2:59 PM

0 · Reply

SmallCapGrowth Apr. 13 at 1:49 PM

0 · Reply

IChiGOdoranZ Apr. 10 at 6:24 PM

0 · Reply

IChiGOdoranZ Apr. 10 at 5:53 PM

$DYAI Indicators Summary #tradingview https://www.tradingview.com/symbols/NASDAQ-DYAI/technicals/

0 · Reply

IChiGOdoranZ Apr. 10 at 1:07 PM

0 · Reply

Glopolon Apr. 9 at 10:06 PM

$DYAI Poster from WVC https://d2ghdaxqb194v2.cloudfront.net/2606/199728.pdf

0 · Reply

Glopolon Apr. 9 at 10:06 PM

$DYAI https://d2ghdaxqb194v2.cloudfront.net/2606/199727.pdf Presentation material from World Vaccine Congress

0 · Reply

IChiGOdoranZ Apr. 7 at 5:20 PM

0 · Reply

IChiGOdoranZ Apr. 7 at 4:51 PM

$DYAI #NASDAQ The Engine of Innovation: Dyadic and Proliant’s Commercial Breakthrough.Perfect Match. https://www.youtube.com/watch?v=AFbJ_3uuzLU

0 · Reply

IChiGOdoranZ Apr. 7 at 12:56 PM

$DYAI Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before Long https://finance.yahoo.com/markets/stocks/articles/analysts-expect-breakeven-dyadic-international-122804108.html

0 · Reply

Thebullrun Apr. 1 at 9:30 PM

$DYAI #DYAI #NASDAQ Dyadic Applied BioSolutions has entered into a commercial distribution partnership with IBT Bioservices to bring Dyadic-produced recombinant proteins to the global research market Through this OEM agreement, IBT will commercialize Dyadic’s animal-free recombinant proteins through its established sales channels, expanding market access and supporting Dyadic’s transition toward product-based revenue.Initial products are expected to include recombinant DNase I and recombinant transferrin for research-use-only (RUO) applications This partnership represents an important milestone as Dyadic continues moving from platform development to commercial executionplacing products into established distribution channels and building durable revenue streams. Read the full announcement: https://dyadic.com/dyadic-applied-biosolutions-announces-commercial-distribution-partnership-with-ibt-bioservices/ #Biotechnology #LifeSciences #ProteinProduction #CellCulture #RecombinantProteins

0 · Reply

Glopolon Mar. 31 at 4:21 PM

$DYAI PFNX Pseudomonas can not do Human-like glycosylation. Many platform can't do it. That was a hurdle for C1 to pass, moving from Biofuel production to Pharma potential.. https://dyadic.com/dyadic-announces-achieving-human-like-glycan-structures-from-its-engineered-c1-cell-line/

0 · Reply

SmallCapGrowth Mar. 30 at 6:35 PM

$DYAI #NASDAQ The Engine of Innovation: - All Day Stocks https://investorshangout.com/post/view?id=6822218

0 · Reply

SmallCapGrowth Mar. 30 at 3:16 PM

BB's Stock Haven : $DYAI #NASDAQ The Engine of Innovation: Dyadic and Proliant’s Commercial Breakthrough.Perfect Match.... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177449828 via @Investors_Hub

0 · Reply

SmallCapGrowth Mar. 30 at 2:03 PM

$DYAI #NASDAQ The Engine of Innovation: Dyadic and Proliant’s Commercial Breakthrough.Perfect Match. https://www.youtube.com/watch?v=AFbJ_3uuzLU&t=20s #biotechnology #stocks #DYAI @TheBullRunShow @DAVANZO

0 · Reply

ZacksSCR Mar. 30 at 1:35 PM

$DYAI: Introducing AlbuFree DX https://buff.ly/FUA2hOI

0 · Reply

DARKP00L Mar. 30 at 10:41 AM

$DYAI 06:34 on Mar. 30 2026 Dyadic International Gets Nasdaq Warning Over Listing Rules, Faces Delisting Risk #tradeideas

0 · Reply

Glopolon Mar. 27 at 5:59 PM

$DYAI PFNX only had limited Pseudomonas as protein producer, and it went for https://investor.ligand.com/news-and-events/press-releases/news-details/2020/Ligand-Completes-Acquisition-of-Pfenex-Inc--10-01-2020/default.aspx

1 · Reply

Glopolon Mar. 27 at 2:39 PM

$DYAI IIBR moved from HEK cells to C1.. https://dyadic.com/dyadic-advances-collaboration-with-israel-institute-for-biological-research-iibr-targeting-bio-threats-and-emerging-disease-solutions/

1 · Reply

Glopolon Mar. 27 at 2:37 PM

$DYAI Tested and proven on the World stage. By many leading virologists.

0 · Reply

Market Cap	31.31M
Revenue (ttm)	3.09M
Net Income (ttm)	-7.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-238.19%
Debt to Equity Ratio	0.00

Volume	58,600
Avg Vol	74,364
Day's Range	N/A - N/A
Shares Out	36.44M
Stochastic %K	46%
Beta	1.21
Analysts	Strong Sell
Price Target	$6.00